Literature DB >> 24043992

Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Paulo Arnaldo1, Ricardo Estevão Thompson, Márcia Quinhones Lopes, Philip Noel Suffys, Adalberto Rezende Santos.   

Abstract

BACKGROUND: The cytochrome P450 enzymes (CYP) play an important role in the metabolism of many therapeutic agents. The activities of different enzymes exhibit variability in different populations, which causes variations in drug response or toxicity. The CYP2B6 and CYP2C8 enzymes are encoded by polymorphic genes characterised by different single nucleotide polymorphisms (SNPs). Several of these CYP variants are often associated with slow metabolism phenotypes. This study aimed to analyse the frequencies of allelic variants of CYP2B6 and CYP2C8 in the Mozambican population.
METHODS: Using a polymerase chain reaction and restriction fragment length polymorphism assay (PCR-RFLP), the frequencies of the allelic variants of CYP2B6 (c.64C>T, c.516G>T, c.777C>A, c.785A>G, c.1459C>T) and CYP2C8 (c.805A>T, c.416G>A, c.1196A>G, c.792C>G) were determined in 360 Mozambican blood donors.
RESULTS: The frequencies of the allelic variants of the CYP2B6 gene were 0.057, 0.426, 0.0, 0.410, and 0.004. For the CYP2C8 gene, the frequencies of the allelic variants were 0.160, 0.048, 0.0, and 0.005. No significant differences were observed between the gender and geographic distribution of volunteers around the country.
CONCLUSION: The frequencies of the allelic variants of the CYP2B6 and CYP2C8 genes were found to be homogeneously distributed in the Mozambican population and were comparable to other African populations. Further studies are required to explore the impact of these variants on the clinical response (efficacy and toxicity) of drugs, including antimalarials.

Entities:  

Keywords:  CYP2B6; CYP2C8; allele frequency; polymorphism

Year:  2013        PMID: 24043992      PMCID: PMC3773348     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  45 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

Authors:  Masahiro Hiratsuka; Yoh Takekuma; Naomi Endo; Kaori Narahara; Samar Ismail Hamdy; Yukinaga Kishikawa; Masaki Matsuura; Yasuyuki Agatsuma; Tomoko Inoue; Michinao Mizugaki
Journal:  Eur J Clin Pharmacol       Date:  2002-08-14       Impact factor: 2.953

3.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Authors:  D Dai; D C Zeldin; J A Blaisdell; B Chanas; S J Coulter; B I Ghanayem; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-10

4.  Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Marianne Ridderström; Collen M Masimirembwa
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

5.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

6.  Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana.

Authors:  Susanne Röwer; Ulrich Bienzle; Alexander Weise; Ulrike Lambertz; Thomas Forst; Rowland N Otchwemah; Andreas Pfützner; Frank P Mockenhaupt
Journal:  Trop Med Int Health       Date:  2005-12       Impact factor: 2.622

7.  The major phenobarbital-inducible cytochrome P-450 gene subfamily (P450IIB) mapped to the long arm of human chromosome 19.

Authors:  I Santisteban; S Povey; E A Shephard; I R Phillips
Journal:  Ann Hum Genet       Date:  1988-05       Impact factor: 1.670

8.  Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.

Authors:  Xue-Qing Li; Anders Björkman; Tommy B Andersson; Lars L Gustafsson; Collen M Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

9.  Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.

Authors:  George O Adjei; Kim Kristensen; Bamenla Q Goka; Lotte C G Hoegberg; Michael Alifrangis; Onike P Rodrigues; Jorgen A L Kurtzhals
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

10.  High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.

Authors:  Christopher Nyakutira; Daniel Röshammar; Emmanuel Chigutsa; Prosper Chonzi; Michael Ashton; Charles Nhachi; Collen Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2007-12-05       Impact factor: 2.953

View more
  14 in total

1.  Corrections of Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Mostafa Saadat
Journal:  Malays J Med Sci       Date:  2016-10-05

2.  The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.

Authors:  Monkgomotsi J Maseng; Leabaneng Tawe; Prisca K Thami; Sikhulile Moyo; Ishmael Kasvosve; Vladimir Novitsky; Max Essex; Gianluca Russo; Simani Gaseitsiwe; Giacomo M Paganotti
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

Review 3.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

4.  Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.

Authors:  Cheedy Jaja; Latanya Bowman; Leigh Wells; Niren Patel; Hongyan Xu; Matt Lyon; Abdullah Kutlar
Journal:  Clin Transl Sci       Date:  2015-02-02       Impact factor: 4.689

5.  Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population.

Authors:  Sagheer Ahmed; Saeed Khan; Kholood Janjua; Imran Imran; Arif Ullah Khan
Journal:  Mol Genet Genomic Med       Date:  2021-02-18       Impact factor: 2.183

6.  Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.

Authors:  Karol J Marwa; Theresa Schmidt; Maria Sjögren; Omary M S Minzi; Erasmus Kamugisha; Göte Swedberg
Journal:  Malar J       Date:  2014-11-03       Impact factor: 2.979

7.  Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Authors:  Nilesh B Bhatt; Elisabeth Baudin; Bindiya Meggi; Carlota da Silva; Aurélie Barrail-Tran; Valérie Furlan; Beatriz Grinsztejn; Maryline Bonnet; Anne-Marie Taburet
Journal:  J Antimicrob Chemother       Date:  2014-09-18       Impact factor: 5.790

8.  DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions.

Authors:  Zhaohui Liang; Jimmy Xiangji Huang; Xing Zeng; Gang Zhang
Journal:  BMC Med Genomics       Date:  2016-08-10       Impact factor: 3.063

Review 9.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

Review 10.  Disease burden and the role of pharmacogenomics in African populations.

Authors:  K L Mpye; A Matimba; K Dzobo; S Chirikure; A Wonkam; C Dandara
Journal:  Glob Health Epidemiol Genom       Date:  2017-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.